Literature DB >> 9989833

Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors.

R Hoshino1, Y Chatani, T Yamori, T Tsuruo, H Oka, O Yoshida, Y Shimada, S Ari-i, H Wada, J Fujimoto, M Kohno.   

Abstract

The 41-kDa and 43-kDa mitogen-activated protein (MAP) kinases play a pivotal role in the mitogenic signal transduction pathway and are essential components of the MAP kinase cascade, which includes MAP kinase kinase (MEK) and Raf-1. As aberrant activation of signal transducing molecules such as Ras and Raf-1 has been linked with cancer, we examined whether constitutive activation of the 41-/43-kDa MAP kinases is associated with the neoplastic phenotype of 138 tumor cell lines and 102 primary tumors derived from various human organs. Constitutive activation of the MAP kinases was observed in 50 tumor cell lines (36.2%) in a rather tissue-specific manner: cell lines derived from pancreas, colon, lung, ovary and kidney showed especially high frequencies with a high degree of MAP kinase activation, while those derived from brain, esophagus, stomach, liver and of hematopoietic origin showed low frequencies with a limited degree of MAP kinase activation. We also detected constitutive activation of the 41-/43-kDa MAP kinases in a relatively large number of primary human tumors derived from kidney, colon and lung tissues but not from liver tissue. Many tumor cells, in which point mutations of ras genes were detected, showed constitutive activation of MAP kinases, however, there were also many exceptions to this observation. In contrast, the activation of the 41-/43-kDa MAP kinases was accompanied by the activation of Raf-1 in the majority of tumor cells and was completely associated with the activation of MEK and p90rsk in all the tumor cells examined. These results suggest that the constitutive activation of 41-/43-kDa MAP kinases in tumor cells is not due to the disorder of MAP kinases themselves, but is due to the disorder of Raf-1, Ras, or some other signaling molecules upstream of Ras.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9989833     DOI: 10.1038/sj.onc.1202367

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  175 in total

1.  Identification of predictive markers of response to the MEK1/2 inhibitor selumetinib (AZD6244) in K-ras-mutated colorectal cancer.

Authors:  John J Tentler; Sujatha Nallapareddy; Aik Choon Tan; Anna Spreafico; Todd M Pitts; M Pia Morelli; Heather M Selby; Maria I Kachaeva; Sara A Flanigan; Gillian N Kulikowski; Stephen Leong; John J Arcaroli; Wells A Messersmith; S Gail Eckhardt
Journal:  Mol Cancer Ther       Date:  2010-10-05       Impact factor: 6.261

2.  Constitutive K-RasG12D activation of ERK2 specifically regulates 3D invasion of human pancreatic cancer cells via MMP-1.

Authors:  Gregory P Botta; Mauricio J Reginato; Maximilian Reichert; Anil K Rustgi; Peter I Lelkes
Journal:  Mol Cancer Res       Date:  2011-12-08       Impact factor: 5.852

3.  Up-regulation of pro-apoptotic protein Bim and down-regulation of anti-apoptotic protein Mcl-1 cooperatively mediate enhanced tumor cell death induced by the combination of ERK kinase (MEK) inhibitor and microtubule inhibitor.

Authors:  Takumi Kawabata; Susumu Tanimura; Kohei Asai; Ryohei Kawasaki; Yumi Matsumaru; Michiaki Kohno
Journal:  J Biol Chem       Date:  2012-01-23       Impact factor: 5.157

4.  Inhibition of MEK/ERK1/2 sensitizes lymphoma cells to sorafenib-induced apoptosis.

Authors:  Tri K Nguyen; Nicholas Jordan; Jonathan Friedberg; Richard I Fisher; Paul Dent; Steven Grant
Journal:  Leuk Res       Date:  2010-02-01       Impact factor: 3.156

Review 5.  Growth factor signaling pathways as targets for prevention of epithelial carcinogenesis.

Authors:  Okkyung Rho; Dae Joon Kim; Karou Kiguchi; John Digiovanni
Journal:  Mol Carcinog       Date:  2010-07-20       Impact factor: 4.784

Review 6.  Modulation of protein kinase signaling cascades by palytoxin.

Authors:  Elizabeth V Wattenberg
Journal:  Toxicon       Date:  2010-11-09       Impact factor: 3.033

Review 7.  Molecular genesis of non-muscle-invasive urothelial carcinoma (NMIUC).

Authors:  Courtney Pollard; Steven C Smith; Dan Theodorescu
Journal:  Expert Rev Mol Med       Date:  2010-03-25       Impact factor: 5.600

Review 8.  The ERK cascade: a prototype of MAPK signaling.

Authors:  Hadara Rubinfeld; Rony Seger
Journal:  Mol Biotechnol       Date:  2005-10       Impact factor: 2.695

9.  Sprouty2 attenuates epidermal growth factor receptor ubiquitylation and endocytosis, and consequently enhances Ras/ERK signalling.

Authors:  Esther Sook Miin Wong; Chee Wai Fong; Jormay Lim; Permeen Yusoff; Boon Chuan Low; Wallace Y Langdon; Graeme R Guy
Journal:  EMBO J       Date:  2002-09-16       Impact factor: 11.598

10.  Comparison of KRAS/BRAF mutations between primary tumors and serum in colorectal cancer: Biological and clinical implications.

Authors:  Xingxiang Pu; Zhizhong Pan; Ying Huang; Ying Tian; Hongqiang Guo; Lin Wu; Xuexing He; Xinggui Chen; Shaodan Zhang; Tongyu Lin
Journal:  Oncol Lett       Date:  2012-10-10       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.